Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Combination therapies and patient stratification with bispecific anti-EGFR/c-Met antibodies

Combination therapies and patient stratification with bispecific anti-EGFR/c-Met antibodies

US Patent 11459391 · Granted Oct 4, 2022

Estimated economic value: $461,589,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Combination therapies with bispecific anti-EGFR/c-met antibodies and third gener2025
EGFR and C-met fibronectin type III domain binding molecules2025
Bispecific EGFR/c-Met antibodies2025
Treatment of patients having c-met exon 14 skipping mutations2025
Combination therapies and patient stratification with bispecific anti-EGFR/c-Met2025
Combination therapies and patient stratification with bispecific anti-EGFR/c-Met2025
Combination therapies with bispecific anti-EGFR/c-Met antibodies and third gener2024
EGFR and c-Met fibronectin type III domain binding molecules2021
Cysteine engineered fibronectin type III domain binding molecules2020
EGFR and C-Met fibronectin type III domain binding molecules2017
EGFR and c-Met fibronectin type III domain binding molecules2017
Bispecific EGFR/c-Met antibodies2017